Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 8/20 | 0.61 |
| ▸ | MGLL | Q99685 | 5/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.51 |
| ▸ | TSHR | P16473 | 4/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.51 |
| ▸ | USP2 | O75604 | 4/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30420371 | 0.91 | FAAH (0.61) | FAAHMGLLCYP2D6TSHRCYP3A4 | |
| SCHEMBL20567357 | 0.91 | FAAH (0.61) | FAAHMGLLCYP2D6TSHRCYP3A4 | |
| SCHEMBL20920512 | 0.91 | MGLL (0.70) | FAAHMGLLCYP2D6TSHRCYP3A4 | |
| SCHEMBL24970232 | 0.88 | FAAH (0.79) | FAAHMGLLCYP2D6TSHRCYP3A4 | |
| SCHEMBL20567742 | 0.88 | FAAH (0.78) | FAAHMGLL | |
| SCHEMBL30419949 | 0.88 | FAAH (0.78) | FAAHMGLL | |
| SCHEMBL20566988 | 0.88 | FAAH (0.70) | FAAHMGLL | |
| SCHEMBL30421184 | 0.88 | FAAH (0.70) | FAAHMGLL | |
| SCHEMBL20566733 | 0.87 | FAAH (0.66) | FAAHMGLL | |
| SCHEMBL30420407 | 0.87 | FAAH (0.66) | FAAHMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | H. LUNDBECK A/S (DK) | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230219897-A1 | PYRAZOLE MAGL INHIBITORS | MGLL, PNLIP, LPL | FAAH 33/4885MGLL 1/4885CYP2D6 472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.